Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC).

Objective: To establish whether synovial pathobiology improves current clinical classification and prognostic algorithms in early inflammatory arthritis and identify predictors of subsequent biological therapy requirement.Methods: 200 treatment-naïve patients with early arthritis were classified as...

Descripción completa

Detalles Bibliográficos
Publicado en:Annals of the Rheumatic Diseases Vol. 78; no. 12; pp. 1642 - 1653
Autores principales: Lliso-Ribera, Gloria, Humby, Frances, Lewis, Myles, Nerviani, Alessandra, Mauro, Daniele, Rivellese, Felice, Kelly, Stephen, Hands, Rebecca, Bene, Fabiola, Ramamoorthi, Nandhini, Hackney, Jason A., Cauli, Alberto, Choy, Ernest H., Filer, Andrew, Taylor, Peter C., McInnes, Iain, Townsend, Michael J., Pitzalis, Costantino
Formato: pictorial research tables/charts Journal Article
Publicado: Elsevier B.V. Dec2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139712916&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139712916
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00034967
        ANR
      jtl: Annals of the Rheumatic Diseases
      issn: 00034967
      maglogo: N
    pubinfo:
      dt: Dec2019
      vid: 78
      iid: 12
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        139712916
        139712916
        NLM31582377
        139712916
        10.1136/annrheumdis-2019-215751
        NLM31582377
        139712916
      ppf: 1642
      ppct: 11
      formats:
      tig:
        atl: Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC).
      aug:
        au:
          Lliso-Ribera, Gloria
          Humby, Frances
          Lewis, Myles
          Nerviani, Alessandra
          Mauro, Daniele
          Rivellese, Felice
          Kelly, Stephen
          Hands, Rebecca
          Bene, Fabiola
          Ramamoorthi, Nandhini
          Hackney, Jason A.
          Cauli, Alberto
          Choy, Ernest H.
          Filer, Andrew
          Taylor, Peter C.
          McInnes, Iain
          Townsend, Michael J.
          Pitzalis, Costantino
        affil: Centre of Experimental Medicine and Rheumatology, William Harvey Research Institute, London, UK.
      sug:
        subj:
          Arthritis, Rheumatoid Therapy
          Biological Therapy Methods
          Synovial Membrane
          Algorithms
          Human
          Disease Progression
          Prospective Studies
          Arthritis, Rheumatoid Diagnosis
          Male
          Female
          Synovial Membrane Metabolism
          Ultrasonography
          Severity of Illness Indices
          Arthritis, Rheumatoid Classification
          Antirheumatic Agents Therapeutic Use
          Prognosis
          Biopsy
          Middle Age
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Funding Source
          Middle Aged: 45-64 years
          Male
          Female
      ab: Objective: To establish whether synovial pathobiology improves current clinical classification and prognostic algorithms in early inflammatory arthritis and identify predictors of subsequent biological therapy requirement.Methods: 200 treatment-naïve patients with early arthritis were classified as fulfilling RA1987 American College of Rheumatology (ACR) criteria (RA1987) or as undifferentiated arthritis (UA) and patients with UA further classified into those fulfilling RA2010 ACR/European League Against Rheumatism (EULAR) criteria. Treatment requirements at 12 months (Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARDs) vs biologics vs no-csDMARDs treatment) were determined. Synovial tissue was retrieved by minimally invasive, ultrasound-guided biopsy and underwent processing for immunohistochemical (IHC) and molecular characterisation. Samples were analysed for macrophage, plasma-cell and B-cells and T-cells markers, pathotype classification (lympho-myeloid, diffuse-myeloid or pauci-immune) by IHC and gene expression profiling by Nanostring.Results: 128/200 patients were classified as RA1987, 25 as RA2010 and 47 as UA. Patients classified as RA1987 criteria had significantly higher levels of disease activity, histological synovitis, degree of immune cell infiltration and differential upregulation of genes involved in B and T cell activation/function compared with RA2010 or UA, which shared similar clinical and pathobiological features. At 12-month follow-up, a significantly higher proportion of patients classified as lympho-myeloid pathotype required biological therapy. Performance of a clinical prediction model for biological therapy requirement was improved by the integration of synovial pathobiological markers from 78.8% to 89%-90%.Conclusion: The capacity to refine early clinical classification criteria through synovial pathobiological markers offers the potential to predict disease outcome and stratify therapeutic intervention to patients most in need.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N